Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 15/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SCN2B | O60939 | 1/20 | 0.33 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.33 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17428427 | 0.81 | SCN9A (0.42) | SCN9A | |
| SCHEMBL19075585 | 0.78 | SCN9A (0.43) | SCN9ACYP3A4CYP2C9SCN2BSCN1B | |
| SCHEMBL27849367 | 0.71 | SCN9A (0.47) | SCN9ACYP3A4CYP2C9SCN2BSCN1B | |
| Tert-Butyl Formate SCHEMBL27849369 | 0.70 | SCN9A (0.41) | SCN9ACYP3A4CYP2C9SCN2BSCN1B | |
| SCHEMBL21075813 | 0.70 | DRD2 (0.42) | — | |
| SCHEMBL1745322 | 0.66 | SCN9A (0.51) | SCN9ACYP3A4CYP2C9 | |
| SCHEMBL16900306 | 0.66 | ALDH1A1 (0.54) | SCN9A | |
| SCHEMBL17485945 | 0.64 | CCNT1 (0.40) | — | |
| SCHEMBL1094621 | 0.62 | SCN9A (0.45) | SCN9A | |
| SCHEMBL16130007 | 0.62 | ALDH1A1 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190662-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | RDX, C1R, MTX1 | SCN9A 2337/4885CYP3A4 594/4885CYP2C9 692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.